Trial Profile
Phase II trials in aggressive/highly metabolic cancers such as pancreatic, triple-negative breast, and colorectal cancers.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2023
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 08 Feb 2023 According to a BPG Bio media release, Berg Pharma has been acquired by BPG Bio.
- 14 Jun 2012 New trial record